Benzinga

España
Italia
대한민국
日本
Français
Benzinga Edge
Benzinga Research
Benzinga Pro

  • Get Benzinga Pro
  • Data & APIs
  • Events
  • Premarket
  • Advertise
Contribute
España
Italia
대한민국
日本
Français

Benzinga

  • Premium Services
  • Financial News
    Latest
    Earnings
    Guidance
    Dividends
    M&A
    Buybacks
    Interviews
    Management
    Offerings
    IPOs
    Insider Trades
    Biotech/FDA
    Politics
    Healthcare
    Small-Cap
  • Markets
    Pre-Market
    After Hours
    Movers
    ETFs
    Options
    Cryptocurrency
    Commodities
    Bonds
    Futures
    Mining
    Real Estate
    Volatility
  • Ratings
    Analyst Color
    Downgrades
    Upgrades
    Initiations
    Price Target
  • Investing Ideas
    Trade Ideas
    Long Ideas
    Short Ideas
    Technicals
    Analyst Ratings
    Analyst Color
    Latest Rumors
    Whisper Index
    Stock of the Day
    Best Stocks & ETFs
    Best Penny Stocks
    Best S&P 500 ETFs
    Best Swing Trade Stocks
    Best Blue Chip Stocks
    Best High-Volume Penny Stocks
    Best Small Cap ETFs
    Best Stocks to Day Trade
    Best REITs
  • Money
    Investing
    Cryptocurrency
    Mortgage
    Insurance
    Yield
    Personal Finance
    Forex
    Startup Investing
    Real Estate Investing
    Prop Trading
    Credit Cards
    Stock Brokers
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
Unusual Options Activity Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Screeners
Stock Screener
Top Momentum Stocks
Top Quality Stocks
Top Value Stocks
Top Growth Stocks
Compare Best Stocks
Best Momentum Stocks
Best Quality Stocks
Best Value Stocks
Best Growth Stocks
Connect With Us
facebookinstagramlinkedintwitteryoutubeblueskymastodon
About Benzinga
  • About Us
  • Careers
  • Advertise
  • Contact Us
Market Resources
  • Advanced Stock Screener Tools
  • Options Trading Chain Analysis
  • Comprehensive Earnings Calendar
  • Dividend Investor Calendar and Alerts
  • Economic Calendar and Market Events
  • IPO Calendar and New Listings
  • Market Outlook and Analysis
  • Wall Street Analyst Ratings and Targets
Trading Tools & Education
  • Benzinga Pro Trading Platform
  • Options Trading Strategies and News
  • Stock Market Trading Ideas and Analysis
  • Technical Analysis Charts and Indicators
  • Fundamental Analysis and Valuation
  • Day Trading Guides and Strategies
  • Live Investor Events
  • Pre-market Stock Analysis and News
  • Cryptocurrency Market Analysis and News
Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

  • Terms & Conditions
  • Do Not Sell My Personal Data/Privacy Policy
  • Disclaimer
  • Service Status
  • Sitemap
© 2026 Benzinga | All Rights Reserved
November 19, 2023 10:27 PM 2 min read

GOP-Dem Unity On Cannabis: Is Ohio's Legalization Spurring Nationwide Bipartisan Momentum?

by Maureen Meehan Benzinga Editor
Follow

The recent legalization of recreational marijuana in Ohio marked a significant shift in the United States where now over half the population has access to legal adult-use cannabis in addition to the nearly 80% of the country where medical marijuana is legal. 

Growing public support for cannabis, confirmed in a recent Gallup poll, was exemplified in Ohio in a bipartisan expression among citizens. Its GOP leadership is another story.

In addition to regular Americans, the expanding list of lawmakers speaking out for cannabis reform includes Sen. Kirsten Gillibrand (D-N.Y.) who sent a letter to DEA Administrator Anne Milgram last week suggesting the agency act with “great urgency” to reschedule marijuana. The request was in line with a recommendation in late August from the Department of Health and Human Services to reschedule cannabis.

Federal Efforts Lag Far Behind US States In Cannabis Reform

Despite these changes at the state level, they do not as yet extend to the nearly three million federal employees across the nation who are prohibited from using marijuana due to its status as a federal crime. Contractors are in the same position. That could all change soon.

The Washington Post took a closer look at what's happening inside the beltway where the bipartisan Cannabis Users Restoration of Eligibility Act (CURE) was approved in a 30 to 14 vote in September. The CURE Act seeks to prevent federal government employers from using past marijuana usage as a reason to deny employment or security clearances. Current marijuana usage would remain a disqualifying factor. 

The Post quoted advocates like Morgan Fox, political director of the National Organization for the Reform of Marijuana Laws (NORML) who pointed out that while there is no guarantee that growing national support for cannabis will necessarily result in quick Congressional action on the CURE Act…“there is certainly more justification for it being fast-tracked now that there are millions more potential federal job applicants who could be disqualified from gainful employment in the civil service for behavior that will be lawful very soon.”   

Personal Experience Influences The Debate 

Another co-sponsor of CURE, Rep. Jamie B. Raskin (D-Md.) highlighted the importance of allowing individuals who have used marijuana to serve their country.

With bipartisan support for cannabis legalization on the rise, a comment from NORML's Fox seems to ring true. "Lawmakers generally have been taking notice and being more vocal about their support for incremental and comprehensive reforms.” 

NORML, one of the most successful cannabis advocacy groups in the U.S., was founded in 1970.

Photo: Benzinga edit with images by Kindel Media and 12019 on Pixabay

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.


Posted In:
CannabisGovernmentNewsRegulationsPoliticsMarketsGeneralNancy Mace
Beat the Market With Our Free Pre-Market Newsletter
Enter your email to get Benzinga's ultimate morning update: The PreMarket Activity Newsletter

Rep. Nancy Mace (R-S.C.), a co-sponsor of CURE has often shared her story that led to being prescribed antidepressants, which made her suicidal. Then she discovered cannabis as an alternative. “Cannabis saved my life,” Mace said. “And anyone that was in the same position that I was should not be penalized for using something that has saved their life.”

“The CURE Act will ensure that talented individuals seeking to honorably serve our country are not precluded from doing so simply because they admit to having once used marijuana,” Raskin said in a September press release.

Comments
Loading...